ClinicalTrials.gg
CompletedNCT01466179Updated Aug 18, 2017Results posted

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

A Phase 2 interventional study of Blinatumomab in Acute Lymphoblastic Leukemia, sponsored by Amgen Research (Munich) GmbH. Completed at 39 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-08-18.

Sponsored by Amgen Research (Munich) GmbH (part of Amgen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
225
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Enrollment
12th of 61
225 · median 67
Started
2011
the only one that year
Phase 2
30 of 61
10 open now
Registered
4th of 61
by date
Lead sponsor
5 of 61
Amgen Research (Munich) GmbH

Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 12th largest by enrollment, is the only one that started in 2011, is one of 30 in phase 2, and was the 4th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About blinatumomab

blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The purpose of this study is to confirm whether the bispecific T cell engager antibody blinatumomab (MT103) is effective and safe in the treatment of patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL).

Read the detailed description

Relapsed/refractory B-precursor ALL in adult patients is an aggressive malignant disease with dismal prognosis. Several studies have reported long term survival to be below 10%. Major prognostic factors are duration of first complete remission (CR1) and age. With current salvage chemotherapy, complete remission (CR) rate is low (20 to 30%) in patients in first salvage with short duration (\< one year) of first remission, patients relapsed after first salvage, or patients aged 60 years and older. Duration of CR is usually very short (median disease free survival [DFS]: 2.0-7.5 months). Allogeneic hematopoietic stem cell transplantation (HSCT) may provide a curative treatment option for patients in CR with a satisfactory donor and appropriate clinical status including age, organ function, and remission status. Allogeneic HSCT is not an option in most elderly patients with relapsed ALL. Additional therapeutic approaches are urgently needed.

Blinatumomab is a bispecific single-chain antibody derivative against CD (cluster of differentiation)19 and CD3, designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19-expressing cells. In vitro data indicate CD19+ lymphoma and leukemia cell lines to be extremely sensitive to blinatumomab-mediated cytotoxicity. Blinatumomab has the potential to provide meaningful therapeutic benefits to patients compared with existing treatments for this patient population.

This study consists of a screening period, a treatment period and a follow-up period. Participants receive one to five treatment cycles of blinatumomab at a target dose of 28 μg/day. In the first cycle, the initial dose is 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.

Participants who achieve remission within two cycles of treatment can receive up to three additional cycles of consolidation treatment or proceed to allogeneic HSCT. In the event of progression or relapse within the treatment period, treatment will be terminated. Participants with hematological relapse during the efficacy or safety follow-up period may receive up to three additional cycles of blinatumomab (retreatment) for a maximal total of eight cycles at the investigator´s discretion.

Thirty days after end of the last treatment, participants have an end-of-core-study visit. Following this, there are efficacy follow-up visits at 3, 6, 9, 12, 18 and 24 months at the most after treatment start. Once efficacy follow-up is complete, information on survival collected at least every six months until death or at least until three years after treatment start, whichever occurs earlier (survival follow-up).

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • B-ALL
  • relapsed ALL
  • refractory ALL
  • adult ALL
  • Leukemia
  • Leukemia, Lymphoid
  • precursor cell lymphoblastic leukemia-lymphoma
  • Lymphatic diseases
  • Lymphoproliferative disorders
  • bispecific antibody
  • anti-CD19
  • Immunotherapeutic treatment
  • immunoproliferative disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with Philadelphia chromosome (Ph)-negative B-precursor ALL, with any of the following:

    • with first remission duration less than or equal to 12 months in first salvage or
    • relapsed or refractory after first salvage therapy or
    • relapsed or refractory within 12 months of hematopoietic stem cell transplantation (HSCT)
  • 10% or more blasts in bone marrow
  • In case of clinical signs of additional extramedullary disease:
  • (ECOG) performance status ≤ 2
  • Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Patients with Ph-positive ALL
  • Patients with Burkitt's Leukemia according to World Health organization (WHO) classification
  • History or presence of central nervous system (CNS) pathology
  • Active ALL in the CNS or testes
  • Current disease or history of autoimmune disease with potential CNS involvement
  • HSCT within six weeks prior to start of blinatumomab treatment
  • Allogeneic HSCT within three months prior to start of blinatumomab treatment
  • Any active acute (GvHD), or active chronic GvHD Grade 2 - 4
  • Any systemic therapy against GvHD within two weeks prior to start of blinatumomab treatment
  • Cancer chemotherapy within two weeks prior to start of blinatumomab treatment
  • Radiotherapy within two weeks prior to start of blinatumomab treatment
  • Immunotherapy (e.g., rituximab) within four weeks prior to start of blinatumomab treat-ment
  • Any anti-leukemic product within four weeks prior to start of blinatumomab treatment
  • Treatment with any other investigational medicinal product (IMP) after signature of
  • Eligibility for allogeneic HSCT at the time of enrollment
  • Known to immunoglobulins or to any other component of the IMP formulation
  • Abnormal laboratory values indicative of inadequate renal or liver function
  • History of requiring treatment other than ALL within five years prior to start of blinatumomab treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix
  • Any concurrent disease or medical condition that is deemed to interfere with the conduct of the study
  • Infection with (HIV) or chronic infection with virus or virus
  • Pregnant or nursing women
  • Women of not willing to use an effective form of . Male patients not willing to ensure not to beget a child
  • Previous treatment with blinatumomab
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.

    Biological: Blinatumomab

Interventions

  • BiologicalBlinatumomab

    Continuous intravenous infusion over four weeks per treatment cycle

    Also known as: AMG103, MT103, BLINCYTO™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: Complete Remission (CR): * bone marrow blasts ≤ 5% * no evidence of disease * full recovery of peripheral blood counts: * platelets \> 100,000/μL, and * absolute neutrophil count (ANC) \> 1,000/μL Complete Remission With Partial Hematological Recovery (CRh\*): * bone marrow blasts ≤ 5% * no evidence of disease * partial recovery of peripheral blood counts: * platelets \> 50,000/μL, and * ANC \> 500/μL.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

Secondary outcomes

  1. Time to Hematological Relapse (Duration of Response)

    Time to hematological relapse was measured for participants in remission during the core study (the time from the first infusion through 30 days after the last infusion), from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death. Hematological relapse is defined as: * proportion of blasts in bone marrow \> 5% after documented CR/CRh\* or * blasts in peripheral blood after documented CR/CRh\*. Time to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

    Time frame: Up to the data cut-off date of 10 October 2013; median observation time was 8.0 months.

  2. Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission

    Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.

    Time frame: Up to the data cut-off date of 10 October 2013. Maximum duration on study was 17.8 months.

  3. Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment

    Complete Remission was defined by the following criteria: * bone marrow blasts ≤ 5% * no evidence of disease * full recovery of peripheral blood counts: * platelets \> 100,000/μL, and * absolute neutrophil count (ANC) \> 1,000/μL

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  4. Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

    Complete Remission With Partial Hematological Recovery was defined by the following criteria: * bone marrow blasts ≤ 5% * no evidence of disease * partial recovery of peripheral blood counts: * platelets \> 50,000/μL, and * ANC \> 500/μL.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  5. Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment

    Partial Remission is defined as bone marrow blasts 6% to 25% with at least a 50% reduction from baseline.

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  6. Relapse-free Survival

    Relapse-free survival was assessed for participants who achieved a complete remission or complete remission with partial hematological recovery during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

    Time frame: Up to the data cut-off date of 10 October 2013; median observation time was 8.9 months.

  7. Event-free Survival

    Event-free survival was calculated from the start date of blinatumomab infusion until the date of bone marrow aspiration at which hematological relapse was first detected, or the date of diagnosis on which the hematological or extramedullary relapse was documented or the date of start of any new therapy for ALL (excluding HSCT), or the date of death, whichever was earlier. Participants who did not achieve complete remission or complete remission with partial hematological recovery during the core study were evaluated as having an event on Day 1. Participants in remission who did not experience hematological relapse, did not receive a new therapy for ALL (excluding HSCT), and did not die were censored on the date of the last available bone marrow aspiration or on the last date of survival follow-up visit, whichever was later. Event free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

    Time frame: Up to the data cut-off date of 10 October 2013; median observation time was 9.8 months.

  8. Overall Survival

    Overall survival was measured for all participants from the time the participant received the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan Meier method.

    Time frame: Up to the data cut-off date of 10 October 2013; median observation time was 9.8 months.

  9. Number of Participants With Treatment-emergent Adverse Events

    Adverse events (AEs) were evaluated for severity according to the the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant incapacity or substantial disruption to conduct normal life functions, is a congenital anomaly or birth defect or is a medically important condition. Progressive disease was not an adverse event, per the protocol, unless it was more severe than expected for the patient. Therefore, many deaths due to progressive disease were not counted as adverse events.

    Time frame: From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 42.2 days.

  10. 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

    The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in remission (CR/CRh\*) following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. Patients alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of patients having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.

    Time frame: From the date of allogeneic HSCT until the data cut-off date of 10 October 2013; median observation time was 7.4 months.

  11. Serum Blinatumomab Concentration at Steady State

    The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the start of the IV infusion or dose step for cycle 1 and cycle 2, respectively. Serum concentrations of blinatumomab were measured using a validated bioassay. The lower limit of quantitation (LLOQ) = 50.0 pg/mL.

    Time frame: Samples were taken before treatment start and on Days 3, 8, 10, 15, 22, and 29 after infusion start during Cycles 1 and 2.

  12. Serum Cytokine Peak Levels

    The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ using enzyme-linked immunosorbent assays or cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the limit of quantification (LOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \< LOQ and \> LOD were reported as measured. Serum IL-4 levels were below detection limit (\< 20 pg/mL) at all time points in all participants studied.

    Time frame: Serum samples were collected on Days 1 and 8 at 2 hours and 6 hours after treatment start, and on Day 2 (24 hours) and Day 3 (48 hours) of each treatment cycle and on Days 9 and 10 after dose step.

  13. Percentage of Participants With a Best Response of Blast Free Hypoplastic or Aplastic Bone Marrow Within 2 Cycles of Treatment

    Blast Free Hypoplastic or Aplastic Bone Marrow was defined as: * bone marrow blasts ≤ 5% * no evidence of disease * insufficient recovery of peripheral counts: platelets ≤ 50,000/μL and/or absolute neutrophil count (ANC) ≤ 500/μL

    Time frame: Within the first 2 cycles of treatment, 12 weeks

  14. Best Response During the Core Study

    Complete Remission (CR): * bone marrow blasts ≤ 5% * no evidence of disease * full recovery of peripheral blood counts: * platelets \> 100,000/μL, and * absolute neutrophil count (ANC) \> 1,000/μL Complete Remission With Partial Hematological Recovery (CRh\*): * bone marrow blasts ≤ 5% * no evidence of disease * partial recovery of peripheral blood counts: * platelets \> 50,000/μL, and * ANC \> 500/μL Blast Free Hypoplastic or Aplastic Bone Marrow: * bone marrow blasts ≤ 5% * no evidence of disease * insufficient recovery of peripheral counts: platelets ≤ 50,000/μL and/or ANC ≤ 500/μL Partial Remission: • bone marrow blasts 6% to 25% with at least a 50% reduction from Baseline.

    Time frame: From the first dose of blinatumomab until 30 days after the end of the last infusion during the core study, or until the data cut-off date of 10 October 2013; a maximum of 7.5 months.

07

Results

Posted Jan 22, 2015

Participant flow

This study was open to adult patients with relapsed / refractory B-precursor acute lymphoblastic leukemia (ALL). The study protocol originally used a Simon 2-stage design and was subsequently expanded to include a third stage. Protocol amendment 4 added an additional cohort of participants for central nervous system evaluations.

Participant flow — Overall Study
MilestoneBlinatumomab
Started189
Completed10
Not completed179
Withdrew: Ongoing in core study2
Withdrew: Physician decision46
Withdrew: Progressive disease43
Withdrew: Adverse event32
Withdrew: Disease relapse23
Withdrew: Lack of efficacy14
Withdrew: Death7
Withdrew: Withdrawal by subject7
Withdrew: Protocol violation2
Withdrew: Other3

Outcome measures

PrimaryPercentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory. Hematological remissions were defined by the following criteria: Complete Remission (CR): * bone marrow blasts ≤ 5% * no evidence of disease * full recovery of peripheral blood counts: * platelets \> 100,000/μL, and * absolute neutrophil count (ANC) \> 1,000/μL Complete Remission With Partial Hematological Recovery (CRh\*): * bone marrow blasts ≤ 5% * no evidence of disease * partial recovery of peripheral blood counts: * platelets \> 50,000/μL, and * ANC \> 500/μL.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment42.9 (35.7 to 50.2)
SecondaryTime to Hematological Relapse (Duration of Response)

Time to hematological relapse was measured for participants in remission during the core study (the time from the first infusion through 30 days after the last infusion), from the time the participant first achieved remission until first documented relapse or death due to disease progression. Participants without documented relapse (hematological or extramedullary) and who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Participants who died without having reported hematological relapse or without showing any clinical sign of disease progression were censored on their date of death. Hematological relapse is defined as: * proportion of blasts in bone marrow \> 5% after documented CR/CRh\* or * blasts in peripheral blood after documented CR/CRh\*. Time to hematological relapse was analyzed by Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

Time frame:
Up to the data cut-off date of 10 October 2013; median observation time was 8.0 months.
Reported as:
Median · months
Time to Hematological Relapse (Duration of Response)
monthsBlinatumomab
Time to Hematological Relapse (Duration of Response)6.7 (5.1 to NA)
SecondaryPercentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission

Participants who were eligible for allogeneic HSCT were those who achieved remission (complete response or complete response with partial recovery of peripheral blood counts) after 2 cycles of blinatumomab treatment, and no further anti-leukemic medication was given before HSCT.

Time frame:
Up to the data cut-off date of 10 October 2013. Maximum duration on study was 17.8 months.
Reported as:
Number · percentage of participants
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission
percentage of participantsBlinatumomab
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT) During Blinatumomab Induced Remission39.5 (28.8 to 51.0)
SecondaryPercentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment

Complete Remission was defined by the following criteria: * bone marrow blasts ≤ 5% * no evidence of disease * full recovery of peripheral blood counts: * platelets \> 100,000/μL, and * absolute neutrophil count (ANC) \> 1,000/μL

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With a Best Response of Complete Remission Within 2 Cycles of Treatment33.3 (26.7 to 40.5)
SecondaryPercentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment

Complete Remission With Partial Hematological Recovery was defined by the following criteria: * bone marrow blasts ≤ 5% * no evidence of disease * partial recovery of peripheral blood counts: * platelets \> 50,000/μL, and * ANC \> 500/μL.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With a Best Response of Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment9.5 (5.7 to 14.6)
SecondaryPercentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment

Partial Remission is defined as bone marrow blasts 6% to 25% with at least a 50% reduction from baseline.

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment2.6 (0.9 to 6.1)
SecondaryRelapse-free Survival

Relapse-free survival was assessed for participants who achieved a complete remission or complete remission with partial hematological recovery during the core study and was measured from the time the participant first achieved remission until first documented relapse or death due to any cause. Participants without a documented relapse (hematological or extramedullary) or who did not die were censored at the time of their last bone marrow assessment or their last survival follow-up visit confirming remission. Relapse free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

Time frame:
Up to the data cut-off date of 10 October 2013; median observation time was 8.9 months.
Reported as:
Median · months
Relapse-free Survival
monthsBlinatumomab
Relapse-free Survival5.9 (4.8 to 8.3)
SecondaryEvent-free Survival

Event-free survival was calculated from the start date of blinatumomab infusion until the date of bone marrow aspiration at which hematological relapse was first detected, or the date of diagnosis on which the hematological or extramedullary relapse was documented or the date of start of any new therapy for ALL (excluding HSCT), or the date of death, whichever was earlier. Participants who did not achieve complete remission or complete remission with partial hematological recovery during the core study were evaluated as having an event on Day 1. Participants in remission who did not experience hematological relapse, did not receive a new therapy for ALL (excluding HSCT), and did not die were censored on the date of the last available bone marrow aspiration or on the last date of survival follow-up visit, whichever was later. Event free survival was estimated using Kaplan-Meier methods and the median observation time was calculated by the reverse Kaplan Meier method.

Time frame:
Up to the data cut-off date of 10 October 2013; median observation time was 9.8 months.
Reported as:
Median · months
Event-free Survival
monthsBlinatumomab
Event-free Survival0.0 (0.0 to 1.0)
SecondaryOverall Survival

Overall survival was measured for all participants from the time the participant received the first treatment of blinatumomab until death due to any cause or the date of the last follow-up. Participants who did not die were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. Overall survival was estimated using Kaplan-Meier methods. The median follow-up time with respect to overall survival was calculated by the reverse Kaplan Meier method.

Time frame:
Up to the data cut-off date of 10 October 2013; median observation time was 9.8 months.
Reported as:
Median · months
Overall Survival
monthsBlinatumomab
Overall Survival6.1 (4.2 to 7.5)
SecondaryNumber of Participants With Treatment-emergent Adverse Events

Adverse events (AEs) were evaluated for severity according to the the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4, as follows: Grade 1 - Mild AE; Grade 2 - Moderate AE; Grade 3 - Severe AE; Grade 4 - Life-threatening or disabling AE; Grade 5 - Death. The investigator used medical judgment to determine if there was a causal relationship (ie, related, unrelated) between an adverse event and blinatumomab. An AE was considered "serious" if it resulted in death, was life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant incapacity or substantial disruption to conduct normal life functions, is a congenital anomaly or birth defect or is a medically important condition. Progressive disease was not an adverse event, per the protocol, unless it was more severe than expected for the patient. Therefore, many deaths due to progressive disease were not counted as adverse events.

Time frame:
From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 42.2 days.
Reported as:
Number · participants
Number of Participants With Treatment-emergent Adverse Events
participantsBlinatumomab
Any adverse event (AE)188
Adverse events of at least CTC grade 3155
Treatment-related adverse events166
Related adverse events of at least CTC grade 3105
Serious adverse events121
Serious adverse events of at least CTC grade 3105
Related serious adverse events69
AEs leading to interruption of blinatumomab63
AEs leading to discontinuation of blinatumomab34
Related AE leading to treatment discontinuation18
AEs leading to death28
Related AEs leading to death3
Secondary100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant

The analysis of 100-day mortality after allogeneic HSCT was assessed for all participants who received an allogeneic HSCT while in remission (CR/CRh\*) following treatment with blinatumomab. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT. Patients alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive. The 100-day mortality rate after allogeneic HSCT was defined as the percentage of patients having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods.

Time frame:
From the date of allogeneic HSCT until the data cut-off date of 10 October 2013; median observation time was 7.4 months.
Reported as:
Number · percentage of participants
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
percentage of participantsBlinatumomab
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant11.3 (0.0 to 23.4)
SecondarySerum Blinatumomab Concentration at Steady State

The steady state concentration of blinatumomab was summarized as the observed concentrations collected at least 10 hours after the start of the IV infusion or dose step for cycle 1 and cycle 2, respectively. Serum concentrations of blinatumomab were measured using a validated bioassay. The lower limit of quantitation (LLOQ) = 50.0 pg/mL.

Time frame:
Samples were taken before treatment start and on Days 3, 8, 10, 15, 22, and 29 after infusion start during Cycles 1 and 2.
Reported as:
Mean · pg/mL
Serum Blinatumomab Concentration at Steady State
pg/mLCycle 1: Blinatumomab 9 μg/DayCycle 1: Blinatumomab 28 μg/DayCycle 2: Blinatumomab 28 μg/Day
Serum Blinatumomab Concentration at Steady State211 ± 258621 ± 502731 ± 444
SecondarySerum Cytokine Peak Levels

The activation of immune effector cells was monitored by the measurement of peripheral blood cytokine levels including interleukin (IL)-2, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α and interferon gamma (IFN)-γ using enzyme-linked immunosorbent assays or cytometric bead assays. The limit of detection of the assay (LOD) was 20 pg/mL and the limit of quantification (LOQ) was 125 pg/mL. Data below LOD were set to 10 pg/mL while data \< LOQ and \> LOD were reported as measured. Serum IL-4 levels were below detection limit (\< 20 pg/mL) at all time points in all participants studied.

Time frame:
Serum samples were collected on Days 1 and 8 at 2 hours and 6 hours after treatment start, and on Day 2 (24 hours) and Day 3 (48 hours) of each treatment cycle and on Days 9 and 10 after dose step.
Reported as:
Mean · pg/mL
Serum Cytokine Peak Levels
pg/mLBlinatumomab
IFN-Ɣ: Cycle 1 Week 1 (N=184)93.1 ± 409
IFN-Ɣ: Cycle 1 Week 2 (N=175)27.4 ± 83.1
IFN-Ɣ: Cycle 2 Week 1 (N=95)22.8 ± 45.8
IFN-Ɣ: Cycle 3 Week 1 (N=41)21.6 ± 27.6
IL-10: Cycle 1 Week 1 (N=184)589 ± 822
IL-10: Cycle 1 Week 2 (N=175)95.7 ± 136
IL-10: Cycle 2 Week 1 (N=95)397 ± 633
IL-10: Cycle 3 Week 1 (N=41)428 ± 941
IL-2: Cycle 1 Week 1 (N=184)24.7 ± 44.6
IL-2: Cycle 1 Week 2 (N=175)10.8 ± 5.21
IL-2: Cycle 2 Week 1 (N=95)11 ± 5.17
IL-2: Cycle 3 Week 1 (N=41)10.3 ± 2.03
IL-6: Cycle 1 Week 1 (N=184)826 ± 2390
IL-6: Cycle 1 Week 2 (N=175)234 ± 681
IL-6: Cycle 2 Week 1 (N=95)315 ± 952
IL-6: Cycle 3 Week 1 (N=41)69.2 ± 114
TNF-α: Cycle 1 Week 1 (N=184)30 ± 125
TNF-α: Cycle 1 Week 2 (N=175)10.3 ± 3.33
TNF-α: Cycle 2 Week 1 (N=95)12.1 ± 15
TNF-α: Cycle 3 Week 1 (N=41)12 ± 7.79
SecondaryPercentage of Participants With a Best Response of Blast Free Hypoplastic or Aplastic Bone Marrow Within 2 Cycles of Treatment

Blast Free Hypoplastic or Aplastic Bone Marrow was defined as: * bone marrow blasts ≤ 5% * no evidence of disease * insufficient recovery of peripheral counts: platelets ≤ 50,000/μL and/or absolute neutrophil count (ANC) ≤ 500/μL

Time frame:
Within the first 2 cycles of treatment, 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Best Response of Blast Free Hypoplastic or Aplastic Bone Marrow Within 2 Cycles of Treatment
percentage of participantsBlinatumomab
Percentage of Participants With a Best Response of Blast Free Hypoplastic or Aplastic Bone Marrow Within 2 Cycles of Treatment9.0 (5.3 to 14.0)
SecondaryBest Response During the Core Study

Complete Remission (CR): * bone marrow blasts ≤ 5% * no evidence of disease * full recovery of peripheral blood counts: * platelets \> 100,000/μL, and * absolute neutrophil count (ANC) \> 1,000/μL Complete Remission With Partial Hematological Recovery (CRh\*): * bone marrow blasts ≤ 5% * no evidence of disease * partial recovery of peripheral blood counts: * platelets \> 50,000/μL, and * ANC \> 500/μL Blast Free Hypoplastic or Aplastic Bone Marrow: * bone marrow blasts ≤ 5% * no evidence of disease * insufficient recovery of peripheral counts: platelets ≤ 50,000/μL and/or ANC ≤ 500/μL Partial Remission: • bone marrow blasts 6% to 25% with at least a 50% reduction from Baseline.

Time frame:
From the first dose of blinatumomab until 30 days after the end of the last infusion during the core study, or until the data cut-off date of 10 October 2013; a maximum of 7.5 months.
Reported as:
Number · percentage of participants
Best Response During the Core Study
percentage of participantsBlinatumomab
Remission (CR/CRh*)43.4 (36.2 to 50.8)
Complete Remission35.4 (28.6 to 42.7)
Complete remission with only partial hematological7.9 (4.5 to 12.8)
Blast free hypoplastic or aplastic bone marrow9.0 (5.3 to 14.0)
Partial remission2.6 (0.9 to 6.1)

Adverse events

Collected over From the start of the first infusion to 30 days after the end of the last infusion in the core study or from the start of the first retreatment cycle infusion to 30 days after the end of the last retreatment cycle, median treatment duration was 42.2 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Blinatumomab—121/189 (64%)186/189 (98.4%)
Most frequent serious events
Showing 10 of 162
Most frequent serious events
EventBlinatumomab
Febrile neutropeniaBlood and lymphatic system disorders16/189
PyrexiaGeneral disorders11/189
PneumoniaInfections and infestations9/189
SepsisInfections and infestations9/189
NeutropeniaBlood and lymphatic system disorders7/189
Device related infectionInfections and infestations7/189
OverdoseInjury, poisoning and procedural complications5/189
EncephalopathyNervous system disorders5/189
TremorNervous system disorders5/189
Confusional statePsychiatric disorders5/189
Most frequent other events
Showing 10 of 54
Most frequent other events
EventBlinatumomab
PyrexiaGeneral disorders106/189
HeadacheNervous system disorders63/189
Oedema peripheralGeneral disorders49/189
NauseaGastrointestinal disorders46/189
HypokalaemiaMetabolism and nutrition disorders44/189
ConstipationGastrointestinal disorders39/189
Febrile neutropeniaBlood and lymphatic system disorders38/189
AnaemiaBlood and lymphatic system disorders37/189
CoughRespiratory, thoracic and mediastinal disorders35/189
DiarrhoeaGastrointestinal disorders34/189

Baseline characteristics

Primary Analysis Set

Age, Continuous
Age, Continuous(years)Blinatumomab
Median39.0 (18 to 79)
Age, Customized
Age, Customized(participants)Blinatumomab
18 to < 35 years90
35 to < 55 years46
55 to < 65 years28
≥ 65 years25
Sex: Female, Male
Sex: Female, Male(Participants)Blinatumomab
Female70
Male119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Blinatumomab
White145
Asian6
Black or African American7
American Indian or Alaska native1
Native Hawaiian or other Pacific Islander1
Other9
Not recorded20
Disease stage entry criteria met
Disease stage entry criteria met(participants)Blinatumomab
Primary refractory16
Relapse ≤ 12 months of allogeneic HSCT39
Entering first salvage; first remission ≤ 12 mo23
Entering second or greater salvage therapies108
No criteria met3
Number of prior relapses
Number of prior relapses(participants)Blinatumomab
016
1107
246
>220
Prior allogeneic HSCT and prior relapses
Prior allogeneic HSCT and prior relapses(participants)Blinatumomab
Prior allogeneic HSCT64
No prior alloHSCT, no prior relapse16
No prior alloHSCT, 1 prior relapse84
No prior alloHSCT, 2 prior relapses22
No prior alloHSCT, > 2 prior relapses3
Number of prior salvage therapies
Number of prior salvage therapies(participants)Blinatumomab
No prior salvage therapy38
1 prior salvage therapy77
2 prior salvage therapies42
> 2 prior salvage therapies32

3 further baseline measures are reported on the registry.

08

Study locations

39 sites
  • City of Hope
    Duarte, California 91010-3000, United States
  • University of California Los Angeles
    Los Angeles, California 90095-1678, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Dana Farber Institute
    Boston, Massachusetts 02215, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Roswell Park Cancer Streets
    Buffalo, New York 14263, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • CHU d'Angers
    Angers, 49933, France
  • Hôpital de l'hôtel Dieu
    Nantes, 44000, France
  • Hôpital Saint Louis
    Paris, 75475, France
  • CHU de Purpan
    Toulouse, 31059, France
  • Charité - Campus Benjamin Franklin
    Berlin, 12200, Germany
  • Klinikum der Goethe Universität, Medizinische Klinik II
    Frankfurt, 60590, Germany
  • Universitätsklinikum Freiburg
    Freiburg, 79106, Germany
  • Medizinische Hochschule Hannover
    Hannover, 30625, Germany
  • Universitätsklinikum Schleswig-Holstein
    Kiel, 24116, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Julius-Maximilians-Universität, Medizinische Klinik und Poliklinik II
    Würzburg, 97080, Germany
  • Ospedali Riuniti di Bergamo
    Bergamo, 24128, Italy
  • Azienda Ospedaliera Antonio Cardarelli
    Naples, 80131, Italy
  • Ospedali Riuniti "Villa Sofia-Cervello"
    Palermo, 90146, Italy
  • Università La Sapienza di Roma
    Rome, 00161, Italy
  • Azienda Ospedaliero-Universitaria
    Turin, 10126, Italy
  • Azienda Ospedaliera di Verona
    Verona, 37134, Italy
  • ICO Hospital Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital Clínic Servei d´Hematologia
    Barcelona, 08036, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen Del Rocio
    Sevilla, 41013, Spain
  • University Hospitals Bristol NHS
    Bristol, BS2 8ED, United Kingdom
  • Royal Free Hampstead NHS Trust
    London, NW3 2QG, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
09

References and documents

Publications

  • Shi Z, Zhu Y, Zhang J, Chen B. Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia. Hematology. 2022 Dec;27(1):642-652. doi: 10.1080/16078454.2022.2074704. PubMed 35622074 ↗
  • Gokbuget N, Kantarjian HM, Bruggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2019 Oct 22;3(20):3033-3037. doi: 10.1182/bloodadvances.2019000457. PubMed 31648325 ↗
  • Zhu M, Kratzer A, Johnson J, Holland C, Brandl C, Singh I, Wolf A, Doshi S. Blinatumomab Pharmacodynamics and Exposure-Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Pharmacol. 2018 Feb;58(2):168-179. doi: 10.1002/jcph.1006. Epub 2017 Sep 18. PubMed 28922466 ↗
  • Barlev A, Lin VW, Katz A, Hu K, Cong Z, Barber B. Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data. Adv Ther. 2017 Jan;34(1):148-155. doi: 10.1007/s12325-016-0447-x. Epub 2016 Nov 21. PubMed 27873237 ↗
  • Zhu M, Wu B, Brandl C, Johnson J, Wolf A, Chow A, Doshi S. Blinatumomab, a Bispecific T-cell Engager (BiTE((R))) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clin Pharmacokinet. 2016 Oct;55(10):1271-1288. doi: 10.1007/s40262-016-0405-4. PubMed 27209293 ↗
  • Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA, Neumann S, Foa R, Litzow M, Ribera JM, Rambaldi A, Schiller G, Bruggemann M, Horst HA, Holland C, Jia C, Maniar T, Huber B, Nagorsen D, Forman SJ, Kantarjian HM. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015 Jan;16(1):57-66. doi: 10.1016/S1470-2045(14)71170-2. Epub 2014 Dec 16. Erratum In: Lancet Oncol. 2015 Apr;16(4):e158. doi: 10.1016/S1470-2045(15)70154-3. PubMed 25524800 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Oct 2013 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2011
First posted
Nov 6, 2011
Start
Dec 2011
Primary completionActual
Oct 2013
CompletionActual
Jan 2017
Results first posted
Jan 22, 2015
Last update
Aug 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01466179
Responsible party
Sponsor
First posted
Nov 6, 2011
Start date
Dec 2011
Primary completion
Oct 2013
Completion
Jan 2017
Results posted
Jan 22, 2015
Last update
Aug 18, 2017

Study contacts

Nicola Gökbuget, MD
principal investigator · Klinikum der Goethe Universität Frankfurt
Max Topp, MD
principal investigator · Julius-Maximilians-Universität, Medizinische Klinik und Poliklinik II, Würzburg
Hagop Kantarjian, MD
principal investigator · MD Anderson Cancer Center, Houston, Texas

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion